文献速递产科

体重指数对米索前列醇引产剂量的影响:阴道与颊部剂型比较

The impact of body mass index on misoprostol dosing for labor induction: a comparison of vaginal and buccal dosage forms.
PubMed 文献 · Am J Obstet Gynecol · 2026-03-04

该研究为NCT02408315试验的二次分析,比较颊部与阴道米索前列醇引产时,不同体重指数(BMI)类别达到活跃产程所需剂量的差异。结果显示,肥胖(BMI≥30 kg/m2)与需要更多米索前列醇剂量相关,且颊部给药独立于BMI需要更多剂量,尤其在肥胖患者中。

要点

  • 肥胖(BMI≥30)患者引产达到活跃产程需更多米索前列醇剂量。
  • 颊部给药比阴道给药需要更多剂量,尤其在肥胖患者中。
  • 不同BMI或给药途径的24小时内阴道分娩率、剖宫产率无显著差异。

核心结论

  • 肥胖(BMI≥30 kg/m2)与达到活跃产程需要更多米索前列醇剂量相关。
  • 颊部给药独立于BMI与更多剂量相关,尤其在肥胖患者中。

研究设计与样本

  • 研究为NCT02408315三盲、安慰剂对照随机对照试验的二次分析,比较阴道与颊部米索前列醇用于足月引产。
  • 共纳入299名完整数据参与者,按BMI分为≤29、30-40、≥41 kg/m2三组。

主要发现

  • 单变量分析中,颊部给药时非肥胖、肥胖、病态肥胖组达到活跃产程所需剂量分别为2.1、2.8、2.9(P=.01),阴道给药组分别为1.9、2.1、2.3(P=.21)。
  • 调整引产指征和种族/民族后,颊部给药需要更多剂量(预期剂量增加24%;P<.005)。
  • 调整后,BMI 30-40组需要更多剂量(预期剂量增加24%;置信限1.01-2.68;P<.047),BMI≥41组(预期剂量增加28%;置信限0.99-3.09;P<.05)。
  • 24小时内阴道分娩率、剖宫产率或胎儿窘迫剖宫产率在不同BMI类别或给药途径间无显著差异。

临床怎么用

  • 对肥胖患者引产时,应预期需要更多米索前列醇剂量,尤其是颊部给药时。
  • 给药途径选择可考虑阴道给药以减少所需剂量,但需结合临床情况。

局限性

  • 本研究为二次分析,原始试验主要结局可能非剂量比较。
  • 样本量有限,病态肥胖组仅71人,置信限较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the increasing prevalence of obesity, strategies to manage induction of labor in obese patients remains underinvestigated. OBJECTIVE: This study aimed to determine whether the number of doses to achieve active labor differed across body mass index categories for buccal misoprostol vs vaginal misoprostol during labor induction. STUDY DESIGN: This was a secondary analysis of the Induction with MisoPROsotol: Oral mucosa versus Vaginal Epithelium study (identification number: NCT02408315), a triple-blinded, placebo-controlled randomized controlled trial of vaginal misoprostol vs buccal misoprostol in term patients undergoing labor induction. The primary outcome for this analysis was the number of doses of misoprostol needed for active labor (defined as a cervical dilation of at least 6 cm). The participants were grouped into 3 body mass index categories (nonobese: ≤29 kg/m2; obese: 30-40 kg/m2; morbidly obese: ≥41 kg/m2). Groups were compared using the Wilcoxon signed-rank test and chi-squared or Fisher exact test. Generalized linear models were used to adjust for ethnicity, race, dosing route, and indication for labor induction. Significance was defined as P<.05. RESULTS: Of 299 participants with complete data, 63 (21%) had a body mass index of ≤29 kg/m2, 165 (55%) had a body mass index between 30 and 40 kg/m2, and 71 (23%) had a body mass index of ≥41 kg/m2. The groups did not differ in age, race, gestational age, nulliparity, initial Bishop score, or route of dosing. There were significantly more non-Hispanic participants in the obese categories (P=.02). A higher proportion of participants with obesity or morbid obesity had diabetes mellitus (6.4% in the nonobese group vs 13.9% in the obese group vs 14.1% in the morbidly obese group) or a hypertensive disorder (7.9% in the nonobese group vs 24.9% in the obese group vs 26.8% in the morbidly obese group) as the primary indication for labor induction (P=.03). In the univariate analysis, compared with the nonobese group, more doses of misoprostol were needed to achieve active labor in the obese and morbidly obese groups when dosed buccally (2.1 vs 2.8 vs 2.9, respectively; P=.01) but not when dosed vaginally (1.9 vs 2.1 vs 2.3, respectively; P=.21). The rates of vaginal delivery in <24 hours, cesarean delivery, or cesarean delivery for fetal distress did not significantly differ across body mass index category or dosing route. When adjusting for indication for labor induction and self-reported race/ethnicity, buccal dosing required more doses to achieve active labor, regardless of body mass index (24% more expected doses; P<.005). Similarly, when controlling for indication for labor induction and self-reported race/ethnicity, obesity was independently associated with requiring more doses for active labor for both dosage routes (body mass index of 30-40 kg/m2: 24% more expected doses; confidence limits of 1.01-2.68; P<.047; body mass index of ≥41 kg/m2: 28% more expected doses; confidence limits of 0.99-3.09; P<.05). CONCLUSION: Obesity (body mass index of ≥30 kg/m2) was associated with the need for more misoprostol doses to achieve active labor. In addition, buccal dosing was independently associated with a higher number of doses than vaginal dosing, especially in patients with obesity.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bynarowicz TM, Bhamidipalli SS, Flannery KM, et al. The impact of body mass index on misoprostol dosing for labor induction: a comparison of vaginal and buccal dosage forms. Am J Obstet Gynecol. 2026. PMID: 41791559. doi:10.1016/j.ajog.2026.02.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。